VCU Massey Cancer Center


2020 Archive

Massey scientists awarded $2.6M to develop novel therapies for liver cancer

Scientists at VCU Massey Cancer Center and VCU Institute of Molecular Medicine (VIMM) were awarded $2.6 million to develop targeted therapies to treat the most common and deadliest form of liver cancer.

Continue reading →

Massey scientist awarded $1.6 million to improve current treatments for cancers in plasma and white blood cells

VCU Massey Cancer Center researcher Senthil Radhakrishnan, Ph.D., member of Massey’s Cancer Molecular Genetics research program and assistant professor of pathology at the VCU School of Medicine, was awarded a $1.6 million R01 grant from the National Institute of General Medical Sciences to study the genetic properties that facilitate cellular stress response to proteasome inhibition as a means to inform the development of more effective cancer therapies.

Continue reading →

Logo for Together for Health Virginia Program

Virginia residents asked to partner in research to reduce cancer disparities

VCU Massey Cancer Center is asking local citizens to partner in cancer research designed to identify and address health needs in their own communities. The project called Together for Health – Virginia is a comprehensive health assessment program designed to better understand how social and behavioral patterns as well as financial and environmental factors impact cancer rates. Information from this research will help to improve health care practices and services within communities.

Continue reading →

Andrew Poklepovic reviewing imaging results on his office computer.

Clinical trial tests whether immunotherapy helps prevent melanoma recurrence

A stage 2 clinical trial testing the use of immunotherapy after surgery to reduce melanoma recurrence is currently underway at VCU Massey Cancer Center. Led by Andrew Poklepovic, M.D., the trial is eligible to any adult melanoma who is about to or recently underwent surgery and has no evidence of metastatic disease.

Continue reading →